Home About Us FAQ Policies Contact Site Map
 
 
QUICK SEARCH
   Advanced Search
 
 
 
   
 
Stay updated on your favorite report topics! We are adding hundreds of new reports daily. Receive email alerts when those reports affect you!

Stay on top of your industry.
  
 

Immunotherapy of Cancer
Product Type: Market Research Report Publication Date: Mar 29, 2007
 
Download a sample from "The Infoshop", another service of Global Information.

SUMMARY

INTRODUCTION

Cancer immunotherapeutics, in particular monoclonal antibody-based products and vaccines, are transforming the cancer treatment market and providing a whole new arsenal of weapons. The introduction of the first monoclonal antibody product to the worldwide market for the treatment of cancer in 1998 initiated a cascade of additional monoclonal antibody products for the treatment of cancer that continues unabated. Average annual growth of monoclonal antibody products has stayed in the double digits since the late 1990s. In 2006, antibodies were the single largest class of therapeutics in clinical development with the exception of vaccines. Essentially every biotech and pharmaceutical company, large or small, has a research program that centers on monoclonal antibodies.

The first dedicated off-the-shelf (not patient-specific) cancer vaccine was introduced to the market in 2006. Merck's Gardasil (quadrivalent human papillomavirus recombinant vaccine) was approved by the FDA in June 2006 for the prevention of cervical cancer associated with human papillomavirus (HPV). The approval of Gardasil marks the first time the FDA approved a designated therapeutic cancer vaccine. Gardasil was approved in the E.U. in September 2006. This report discusses the impact of these new and growing classes of cancer drugs, their influence on the market in terms of treatment and revenues, and how they will complement and/or compete with existing products.

The information and analysis presented in this report on cancer immunotherapy products are important assets in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and for consultants to the pharmaceutical and biotechnology industries. The study provides a comprehensive analysis of the current markets for cancer immunotherapy products and, in particular, the market potential of promising drugs, vaccines and technologies under development.

SCOPE OF STUDY

This report contains:

  • Analyses of products and applications in the cancer immunotherapy sector, including biological response modifiers (cytokines), monoclonal antibody-based products, therapeutic vaccines and other cancer immunotherapies.
  • An overview of the global market, including historical data for cancer treatment and therapies, the latest market trends, and 5-year forecasts and estimates through 2012
  • A section on industry structure with strategies employed by Big Pharma as well as top-selling drug patent expirations and how this relates to the overall pharmaceutical industry and biotechnology companies in particular
  • Sections on products and applications with synopses of more than 100 cancer immunotherapy drug and vaccine products, including those currently marketed and those in Phase III or later development
  • Analyses of patents within the past few decades
  • Profiles for important businesses.

METHODOLOGY

The base year for this study is 2006. Figures are based on revenue figures at the manufacturers' level and are projected at 2006 dollar value; that is, inflation is not computed into the projection figures.

This study was prepared from information obtained from product managers, marketing strategists, research executives and others at leading pharmaceutical and biotechnology companies that compete in the market for cancer immunotherapeutics or which have products in development for this market.

INFORMATION SOURCES

The information and analyses presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations. Key information from the business literature was used as to obtain expert opinion on commercial potential and market sizes from industry professionals.

TABLE OF CONTENTS

  • INTRODUCTION
    • CONTRIBUTION OF THE STUDY AND FOR WHOM
    • OBJECTIVES AND GOALS OF THE STUDY
    • STUDY SCOPE AND FORMAT
    • METHODOLOGY
    • INFORMATION SOURCES
    • AUTHOR'S CREDENTIALS
    • RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
    • DISCLAIMER
  • EXECUTIVE SUMMARY
    • Summary Table:
    • GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
    • Summary Figure:
    • GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 ($ MILLIONS)
  • OVERVIEW
    • DEFINITION AND ETIOLOGY OF CANCER
    • CANCER STATISTICS
    • Table 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN 2000 AND 2002 (%)
    • Table 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2006
    • Table 3 CANCER PREVALENCE RATES IN THE U.S., 2003*
    • Table 3 (CONTINUED)
      • IMMUNOTHERAPY OF CANCER
      • TYPES OF CANCER FOR WHICH IMMUNOTHERAPY TREATMENTS EXIST OR ARE LIKELY TO BE INTRODUCED BY 2012
        • BREAST CANCER
        • COLORECTAL CANCER
        • HEAD AND NECK CANCER
        • KIDNEY CANCER
        • LEUKEMIAS
          • Leukemias (Continued)
        • LIVER CANCER
        • LUNG CANCER
        • MALIGNANT MELANOMA
        • MULTIPLE MYELOMA
        • NONHODGKIN'S LYMPHOMA
        • OSTEOSARCOMA
        • OVARIAN CANCER
        • PANCREATIC CANCER
        • PROSTATE CANCER
        • STOMACH CANCER
      • CURRENT METHODS OF TREATMENT
        • SURGERY
        • RADIATION THERAPY
        • PHARMACEUTICAL THERAPY
        • IMMUNOTHERAPY
        • INFLAMMATORY RESPONSE
          • Cell-Mediated Immunity
          • Humoral Immunity
          • Macrophage Processing
          • Nonspecific Immunity
        • CYTOKINES
          • Two Types of Cytokines
        • MONOCYTES
        • PHAGOCYTES
        • SPECIFIC IMMUNITY
          • Lymphocytes
            • B-Cells
            • T-Cells
            • NK Cells
        • CLINICAL APPROACHES TO IMMUNOTHERAPY
          • Passive Cellular Immunotherapy
            • Dealing with Significant Toxicity
          • Passive Humoral Immunotherapy
          • Active Specific Immunotherapy
          • Nonspecific Immunotherapy
        • TYPES OF IMMUNOTHERAPY PRODUCTS
          • Biological Response Modifiers
    • Table 4 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
    • Table 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
    • Table 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
    • Table 6 (CONTINUED)
    • Table 7 TUMOR NECROSIS FACTORS, THEIR NATURAL SOURCES, AND MAJOR EFFECTS
      • Colony Stimulating Factors
        • Treating Neutropenic Fevers
        • A Justified Expense
      • Interferons
        • A Family of Small Proteins
        • Anticancer Effects
        • Side Effects
        • Production of Interferon
        • Interferon-alpha
        • Interferon-beta
          • Interferon-Beta-1a
      • Interleukins
        • Interleukin-2
        • Other Infection-Fighting Cells
        • Side Effects
      • Tumor Necrosis Factor
    • ANTIBODIES
      • ANTIBODY FORMS IN PRODUCTS
        • Abtides
        • Antibody Conjugates
        • Antiserums
        • Bispecific Antibodies
        • Camouflaged Antibodies
        • Chimeric Antibodies
        • Humanized Antibodies
        • Fully Human Antibodies
        • Progenitor Stem Cells
        • Single-Chain Antibodies
        • Synthetic Antibodies
      • VACCINES
        • ANTIGENS: THEIR ROLE IN CANCER VACCINES
        • VACCINE DEVELOPMENT STRATEGIES
        • A SUMMARY OF TWO APPROACHES: LOW-TECH VS. HIGH-TECH
      • TECHNOLOGY ADVANCES
  • PRODUCTS AND APPLICATIONS
    • IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
    • Table 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
      • MECHANISM OF ACTION OF SELECTED IMMUNOTHERAPY PRODUCTS
    • Table 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS
      • BIOLOGICAL RESPONSE MODIFIERS
        • THE MARKET FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER
    • Table 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
    • Figure 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 ($ MILLIONS)
      • COLONY STIMULATING FACTORS
        • MARKETED BRM PRODUCTS FOR THE TREATMENT OF CANCER
    • Table 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
      • Aranesp
      • Granocyte
      • Leukine
      • Neorecormon
      • Neulasta/Neupopeg/Neupogen/Granulokine
      • Neumega
      • Procrit
      • Stemgen
      • The Market for Colony Stimulating Factors
    • Table 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENT BY PRODUCT, THROUGH 2012 ($ MILLIONS)
      • The Market for Colony Stimulating Factors to Treat Cancer
    • Table 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
    • Figure 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
      • Colony Stimulating Factors in Development
    • INTERFERONS
      • Interferon-Alpha
        • Interferon Alpha-2b Products
      • Marketed Interferon Products for the Treatment of Cancer
    • Table 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
      • Infergen
      • Intron A and PEG-Intron/Rebetron
        • PEG-Intron vs. Intron A
      • Multiferon
      • Roferon-A
    • Interferon-Gamma
      • Actimmune/ Imukin
        • The Market for Interferon Products Used in the Treatment of Cancer
    • Table 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 ($ MILLIONS)
      • THE MARKET FOR interFErons TO TREAT CANCER
    • Table 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
    • Figure 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
      • INTERLEUKINS
        • Marketed Interleukin Products for the Treatment of Cancer
    • Table 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
      • ONTAK
      • PROLEUKIN
        • The Market for Interleukin Products for the Treatment of Cancer
    • Table 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 ($ MILLIONS)
      • TUMOR NECROSIS FACTOR INHIBITORS
      • BIOLOGICAL RESPONSE MODIFIERS IN DEVELOPMENT FOR THE TREAMENT OF CANCER
    • Table 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT
      • Actimmune
      • Cintrekedin Besudotox
      • Multikine
        • Clinical Trial Results
        • A Coca-Cola Formula
      • PEG-Intron
      • PRX321
      • Virulizin
    • COMBINATION CYTOKINE-ANTIBODY TECHNOLOGY IN DEVELOPMENT
    • MONOCLONAL ANTIBODY PRODUCTS
    • Table 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.
    • Table 20 (CONTINUED)
      • MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER
        • Avastin
          • Avastin (Continued)
          • Avastin (Continued)
          • The Avastin Advantage
          • Medicare Reimbursement Law Supports Use of Avastin
        • Bexxar
          • Bexxar (Continued)
        • Campath/ MabCampath
        • Erbitux
    • Table 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
    • Table 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
      • Erbitux (Continued)
      • Herceptin
      • Mylotarg
      • Panorex
      • Rituxan/MabThera
        • Rituxan/Mabthera (Continued)
      • Vectibix
      • Zevalin
        • First Radioimmunotherapeutic Drug
        • Results of Trials
        • Sales of Zevalin
    • THE MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR ALL INDICATIONS
      • Monoclonal Antibody Sales by Technology
    • Table 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
    • Figure 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 ($ MILLIONS)
      • Monoclonal Antibody Sales by Target
    • Table 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 ($ MILLIONS)
      • THE MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES TO TREAT CANCER
    • Table 25 GLOBAL MARKET FORECAST FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
    • Table 25 (CONTINUED)
      • THE EUROPEAN MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
    • Table 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER
    • Table 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
    • Figure 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 ($ MILLIONS)
      • MONOCLONAL ANTIBODY PRODUCTS IN DEVELOPMENT FOR THE treatment of cancer
    • Table 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
    • Table 28 (CONTINUED)
    • Table 28 (CONTINUED)
      • Abegrin (formerly Vitaxin)
      • Avastin
      • Campath/MabCampath
      • CP-675,206
      • Denosumab
      • Herceptin
      • HuMax-CD4
      • HuMax-CD20
      • HuMax-EGFr
      • MDX-010
      • Nimotuzumab
      • OvaRex
      • Pemtumomab
      • Rencarex
      • Rituxan/MabThera
    • VACCINES
    • Table 29 TUMOR ANTIGENS USED IN CANCER VACCINES
      • TYPES OF CANCER VACCINES
        • Whole-cell Vaccines
        • Antigen/Adjuvant Vaccines
        • Idiotype Vaccines
        • Autologous versus Allogenic Vaccines
        • Dendritic Cell Vaccines
        • Synthetic Cell Protein Antigens
        • Gangliosides
        • Heat Shock Proteins
      • CANCER VACCINES ON THE WORLDWIDE MARKET
        • Gardasil
        • M-Vax
        • Melacine
        • OncoVax
      • THE MARKET FOR CANCER VACCINES
    • Table 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION
    • Table 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
    • Figure 6 PERCENTAGE OF GLOBAL MARKET HELD BY AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%)
      • CANCER VACCINES IN DEVELOPMENT
    • Table 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS
    • Table 32 (CONTINUED)
    • Table 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT
      • Allovectin-7
        • Allovectin-7 (Continued)
      • BiovaxID
      • Cervarix
      • DCVax-Brain
      • DCVax-Prostate
      • GMK
      • GVAX Prostate Vaccine
      • IGN101
      • Insegia
        • Insegia (Continued)
        • Insegia (Continued)
      • M-Vax
      • Melacine
      • MyVax Personalized Immunotherapy
        • Myvax Personalized ... (Continued)
      • Oncophage
      • OncoVax
      • Panvac-VF
      • Sipuleucel-T
      • Stimuvax
      • TG 4001
      • TG 1042
      • Theratope
    • OTHER IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER
      • MARKETED PRODUCTS
        • Gleevec
        • Iressa
        • Nexavar
        • Revlimid
        • Sprycel
        • Sutent
        • Tarceva
        • Thalomid
        • Velcade
        • The Market for Other Immunotherapy Products for the Treatment of Cancer
    • Table 34 GLOBAL MARKET FORECAST FOR OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 ($ MILLIONS)
      • PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF CANCER
    • Table 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
    • Table 28 (CONTINUED)
    • Table 28 (CONTINUED)
      • Advexin
      • BAY 43-9006
      • Ceplene
      • Dacogen
      • Efaproxyn
      • Genasense
      • Hycamptin
      • INGN 241
      • Junovan
      • Nexavar
      • Onconase
      • Orathecin
      • Pixantrone
      • PTK787
      • Telcyta
      • Thymitaq
      • Torisel
      • Tykerb/Tycerb
      • Velcade
      • Zarnestra
        • Zarnestra (Continued)
  • INDUSTRY
    • BLOCKBUSTER DRUGS ON THE WORLDWIDE PHARMACEUTICAL MARKET APPROACH 100
    • U.S. PHARMACEUTICAL INDUSTRY GROWTH TO INCREASE SLIGHTLY
    • MORE MERGERS, ACQUISITIONS AND LICENSING
      • MORE MERGERS, ACQUISITIONS AND ... (Continued)
    • BIOGENERICS-THE NEXT REVOLUTION
      • BIOGENERICS-THE NEXT ... (Continued)
  • COMPANY PROFILES
    • ABGENIX, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
        • XenoMouse and XenoMax Technologies
        • Technology Advantages
          • Technology Advantages (Continued)
      • CORPORATE STRATEGY
    • ALFACELL CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • AMGEN, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
    • Table 36 AMGEN'S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
      • CORPORATE STRATEGY
    • ANTIGENICS INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
    • Table 37 ANTIGENICS' PRODUCT PIPELINE
      • CORPORATE STRATEGY
    • AVAX TECHNOLOGIES, INC.
      • BUSINESS OVERVIEW
      • PRODUCTS
      • CORPORATE STRATEGY
    • BIOGEN IDEC, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • BIOMIRA INC.
      • EDMONTON R&D PARK
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • CHIRON CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • LEADING PRODUCTS
      • CORPORATE STRATEGY
    • GENENTECH, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • Table 38 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
    • Table 38 (CONTINUED)
    • Table 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
      • GENMAB A/S
        • BUSINESS OVERVIEW
        • FINANCIAL INFORMATION
        • PRODUCTS
        • CORPORATE STRATEGY
      • GENZYME CORPORATION
        • BUSINESS OVERVIEW
        • FINANCIAL INFORMATION
        • PRODUCTS
        • CORPORATE STRATEGY
      • GLAXOSMITHKLINE PLC
        • BUSINESS OVERVIEW
        • FINANCIAL INFORMATION
        • PRODUCTS
      • IMCLONE SYSTEMS, INC.
        • BUSINESS OVERVIEW
        • FINANCIAL INFORMATION
        • PRODUCTS
    • Table 40 IMCLONE SYSTEMS' PRODUCT PIPELINE
      • CORPORATE STRATEGY
    • IMMUNOMEDICS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
    • Table 41 IMMUNOMEDICS' THERAPEUTIC PRODUCT PIPELINE
    • Table 41 (CONTINUED)
      • CORPORATE STRATEGY
    • MEDAREX, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
    • Table 42 MEDAREX'S PRODUCT PIPELINE
      • CORPORATE STRATEGY
    • MEDIMMUNE, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • LEADING PRODUCTS
        • Leading Products (Continued)
    • Table 43 MEDIMMUNE'S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
      • CORPORATE STRATEGY
    • MERCK & COMPANY, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • MILLENNIUM PHARMACEUTICALS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
    • Table 44 MILLENNIUM'S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
      • CORPORATE STRATEGY
    • NORTHWEST BIOTHERAPEUTICS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
    • Table 45 NORTHWEST BIOTHERAPEUTICS' PRODUCT PIPELINE
      • CORPORATE STRATEGY
    • PFIZER CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
        • Corporate Strategy (Continued)
    • PROGENICS PHARMACEUTICALS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • LEADING PRODUCTS
    • Table 46 PROGENICS' PRODUCT PIPELINE
      • CORPORATE STRATEGY
      • PROTEIN DESIGN LABS
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
    • Table 47 PROTEIN DESIGN LABS' PRODUCTS IN PHASE II OR LATER
      • CORPORATE STRATEGY
    • TRANSGENE S/A
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • VIREXX MEDICAL CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
  • LIST OF TABLES
    • Summary Table:
    • GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
    • Table 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN 2000 AND 2002 (%)
    • Table 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2006
    • Table 3 CANCER PREVALENCE RATES IN THE U.S., 2003*
    • Table 4 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
    • Table 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
    • Table 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
    • Table 7 TUMOR NECROSIS FACTORS, THEIR NATURAL SOURCES, AND MAJOR EFFECTS
    • Table 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
    • Table 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS
    • Table 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
    • Table 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
    • Table 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENTBY PRODUCT, THROUGH 2012 ($ MILLIONS)
    • Table 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
    • Table 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
    • Table 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 ($ MILLIONS)
    • Table 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
    • Table 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
    • Table 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 ($ MILLIONS)
    • Table 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT
    • Table 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.
    • Table 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
    • Table 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
    • Table 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
    • Table 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 ($ MILLIONS)
    • Table 25 GLOBAL MARKET FORECAST FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
    • Table 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER
    • Table 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
    • Table 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
    • Table 29 TUMOR ANTIGENS USED IN CANCER VACCINES
    • Table 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION
    • Table 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
    • Table 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS
    • Table 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT
    • Table 34 GLOBAL MARKET FORECAST FOR OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 ($ MILLIONS)
    • Table 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
    • Table 36 AMGEN'S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
    • Table 37 ANTIGENICS' PRODUCT PIPELINE
    • Table 38 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
    • Table 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
    • Table 40 IMCLONE SYSTEMS' PRODUCT PIPELINE
    • Table 41 IMMUNOMEDICS' THERAPEUTIC PRODUCT PIPELINE
    • Table 42 MEDAREX'S PRODUCT PIPELINE
    • Table 43 MEDIMMUNE'S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
    • Table 44 MILLENNIUM'S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
    • Table 45 NORTHWEST BIOTHERAPEUTICS' PRODUCT PIPELINE
    • Table 46 PROGENICS' PRODUCT PIPELINE
    • Table 47 PROTEIN DESIGN LABS' PRODUCTS IN PHASE II OR LATER
  • LIST OF FIGURES
    • Summary Figure:
    • GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 ($ MILLIONS)
    • Figure 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 ($ MILLIONS)
    • Figure 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
    • Figure 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
    • Figure 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 ($ MILLIONS)
    • Figure 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 ($ MILLIONS)
    • Figure 6 PERCENTAGE OF GLOBAL MARKET HELD BY AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%)

Immunotherapy of Cancer

Publisher: Business Communications Co., Inc.

Format Price Order
PDF by E-mail (Single User License) US $4850.00
Hard Copy US $4850.00
PDF by E-mail (Site License) US $5950.00
PDF by E-Mail (Corporate Use License) US $8500.00
All orders are processed by "www.the-infoshop.com". www.the-infoshop.com is another Global Information web site. This transfer is entirely safe.
Copyright© 2008 GII - All Rights Reserved.